Quick Answer
Protein Intake Resistance Training Meta-Analysis has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Effects of Physical Exercise with and Without Nutritional Supplementation on Serum Albumin in Older People: A Systematic Review and Meta-Analysis
Key Takeaways
- 01Effects of Physical Exercise with and Without Nutritional Supplementation on Serum Albumin in Older People: A Systematic Review and Meta-Analysis [Aravena-Sagardia P (2026)]
- 02Randomized clinical trials consistently report mean weight loss ranging from approximately 15% to more than 20% of total body weight, accompanied by improvements in glycemic control, cardiometabolic risk factors, and obesity-related comorbidities [,,]. [Zambrano-Villacres Raynier (2026)]
- 03As a result, pharmacotherapy is increasingly positioned as an important component of contemporary obesity treatment algorithms rather than a secondary or last-line option []. [Zambrano-Villacres Raynier (2026)]
- 0420 20 20 21 22 23 24 25 26 Emerging real-world evidence indicates that a substantial proportion of individuals initiating GLP-1 receptor agonist therapy discontinue treatment within the first year []. [Zambrano-Villacres Raynier (2026)]
The current Migaku evidence database contains 2 reusable source documents for Protein Intake Resistance Training Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation.
- Effects of Physical Exercise with and Without Nutritional Supplementation on Serum Albumin in Older People: A Systematic Review and Meta-Analysis [Aravena-Sagardia P (2026); evidence level 1]
- Randomized clinical trials consistently report mean weight loss ranging from approximately 15% to more than 20% of total body weight, accompanied by improvements in glycemic control, cardiometabolic risk factors, and obesity-related comorbidities [,,]. [Zambrano-Villacres Raynier (2026); evidence level 3]
- As a result, pharmacotherapy is increasingly positioned as an important component of contemporary obesity treatment algorithms rather than a secondary or last-line option []. [Zambrano-Villacres Raynier (2026); evidence level 3]
- 20 20 20 21 22 23 24 25 26 Emerging real-world evidence indicates that a substantial proportion of individuals initiating GLP-1 receptor agonist therapy discontinue treatment within the first year []. [Zambrano-Villacres Raynier (2026); evidence level 3]
- 1 2 3 4 5 6 7 8 9 The therapeutic landscape of obesity management has changed profoundly with the clinical introduction and rapid uptake of glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1RAs) [,]. [Zambrano-Villacres Raynier (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Effects of Physical Exercise with and Without Nutritional Supplementation on Serum Albumin in Older People: A Systematic Review and Meta-Analysis
- Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance